Divalproex Sodium Tablet, Delayed Release
Product Images NDC 71335-2885

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 71335-2885). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 01)

Chemical structure of Divalproex Sodium, showing the sodium salt of valproic acid with illustration of its repetitive molecular units.*

FDA Label Image

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 02)

A bar chart comparing percentages for two studies over one and three years (YR1 and YR3). It shows data for two groups labeled PBO and DVPX, with DVPX displaying higher percentages (60% and 58%) compared to PBO (26% and 29%). The chart likely represents efficacy or outcome measures related to Divalproex Sodium.*

FDA Label Image

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 03)

A cumulative distribution curve graph comparing % reduction in Clinical Psychiatric Scale (CPS) rate for patients treated with Divalproex Sodium versus placebo. The x-axis represents the percentage of patients, and the y-axis shows the percentage reduction in CPS rate from worsening to improvement. The solid line indicates Divalproex Sodium, and the dashed line indicates placebo.*

FDA Label Image

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 04)

A line graph showing the percentage reduction in CPS rate against the percentage of patients for high and low doses of a treatment. The vertical axis ranges from -100% (worsening) to 100% (improvement), while the horizontal axis represents the percentage of patients from 0 to 100%. The graph compares high dose (solid line) and low dose (dashed line) effects.*

FDA Label Image

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 05)

A bar chart comparing placebo and Divalproex Sodium effects across two studies. The vertical axis likely represents a measured outcome level, with placebo bars higher than Divalproex Sodium bars in both studies, illustrating a decrease associated with the drug.*

FDA Label Image

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 1830 2)

FDA Label Image

Label (Lbl713352885)

Label for Divalproex Sodium Delayed Release Tablets USP 250 mg. The label shows storage instructions, quantity of 500 tablets, and mentions Bryant Ranch Prepack as the relabeler and Unichem Laboratories Ltd. as the manufacturer. Includes QR codes and barcodes with NDC 71335-2885-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.